Table 2 Univariable and Multivariable analysis for hepatocellular carcinoma (HCC) recurrence after LT in the entire cohort
Characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
HR | 95%CI | P | aHR | 95%CI | P | |
Male gender (vs female) | 3.95 | 1.25–12.41 | 0.019 | 2.05 | 0.64–6.58 | 0.230 |
Age ≥ 60y (vs < 60y) | 0.84 | 0.55–1.26 | 0.394 |  |  |  |
NAs (TDF vs ETV) | 0.29 | 0.13–0.67 | 0.003 | 0.33 | 0.14–0.75 | 0.008 |
LRT before LT | 0.90 | 0.64–1.27 | 0.558 |  |  |  |
Maximum diameter plus number of lesion > 5 (vs ≤ 5) | 4.28 | 2.50–7.34 |  < 0.001 | 2.32 | 1.32–4.09 | 0.004 |
MAV | 2.27 | 1.61–3.19 |  < 0.001 | 1.22 | 0.84–1.78 | 0.302 |
MIV | 5.41 | 3.25–9.00 |  < 0.001 | 2.55 | 1.48–4.39 |  < 0.001 |
Macrovascular tumor thrombus | 3.97 | 2.81–5.59 |  < 0.001 | 1.84 | 1.25–2.71 | 0.002 |
AFP > 20 ng/ml (vs ≤ 20 ng/ml) | 3.12 | 2.10–4.63 |  < 0.001 | 2.07 | 1.38–3.13 |  < 0.001 |
PT > 14.5 s (vs ≤ 14.5 s) | 1.03 | 0.73–1.45 | 0.884 |  |  |  |
FIB > 1.7 g/L (vs ≤ 1.7 g/L) | 1.56 | 0.95–2.56 | 0.08 |  |  |  |
INR > 1.1 (vs ≤ 1.1) | 0.92 | 0.65–1.31 | 0.662 |  |  |  |
TB > 34.2umol/L (vs ≤ 34.2umol/L) | 1.28 | 0.91–1.80 | 0.154 |  |  |  |
ALB > 36 g/L (vs ≤ 36 g/L) | 0.79 | 0.56–1.11 | 0.181 |  |  |  |
Cr > 116umol/L (vs ≤ 116umol/L) | 0.90 | 0.42–1.93 | 0.788 |  |  |  |
MELD > 15 (vs ≤ 15) | 1.14 | 0.77–1.67 | 0.515 |  |  |  |
HBVDNA > 5log10 copies/ml (vs ≤ 5log10 copies/ml) | 1.14 | 0.68–1.89 | 0.626 |  |  |  |
Poor differentiation | 1.44 | 1.26–1.65 |  < 0.001 | 1.23 | 1.06–1.43 | 0.005 |
Satellite nodule | 2.21 | 1.54–3.18 |  < 0.001 | 1.17 | 0.80–1.71 | 0.418 |
Valley concentration of FK506 (> 10 ng/ml)or Ciclosporinin (> 300 ng/ml) in 1 month after LT | 1.25 | 0.85–1.84 | 0.255 |  |  |  |
Steatosis of donor liver | 0.79 | 0.56–1.11 | 0.172 |  |  |  |
CIT > 300 min (vs ≤ 300 min) | 1.32 | 0.65–2.70 | 0.446 |  |  |  |